Harbour BioMed announced it has entered into an exclusive strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical to develop and commercialize A167, an anti-PD-L1 antibody in Phase 2 clinical development, worldwide outside of the Greater China region.
The companies will also collaborate in developing combination therapies of A167 with other agents for commercialization in their respective territories. The potential value of the partnership exceeds $350 million in addition to royalties.
A167 is an immune-oncology investigational antibody developed by Kelun-Biotech. It binds to immune checkpoint protein PD-L1 and reactivate T cells in the body against cancer cells. The antibody has potential usage in a broad range of solid tumor and hematological malignancies in monotherapy and in combination with other agents. A167 is currently in multiple Phase 1 and Phase 2 clinical trials in China targeting lymphoma and solid tumors.
Under the agreement, Kelun-Biotech will receive upfront, development and regulatory milestones, and commercial milestones based on preset goals, with a potential value of more than $350 million, in addition to royalties based on annual net sales. Harbour will have exclusive rights to develop, manufacture and commercialize A167 in regions outside of Greater China. Both companies will share data generated from their own research and clinical trials to support mono and combination therapies of A167 with other agents for both parties’ development and registration.
Earlier this month Harbour BioMed signed an exclusive license agreement with Glenmark Pharmaceuticals.
Harbour BioMed is a global biopharmaceutical company discovering and developing innovative therapeutics for oncology and immunological diseases. The company’s discovery and development programs are built around its two patented transgenic mouse platforms for therapeutic antibody discovery. Founded in 2016, Harbour BioMed has operation and an R&D site in Shanghai (China), business operations and innovation center including research laboratory in Boston (USA), and an antibody platform innovation center in Rotterdam (Netherlands).
Sichuan Kelun-Biotech Biopharmaceutical (China), a subsidiary of Kelun Pharmaceutical Group, focuses on research and development, registration and global collaboration. Kelun-Biotech currently has over 20 biologics and over 30 innovative small molecule programs, including 5 biologics and 4 innovative small molecule programs in clinical trials.